A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Bradley Sumrow(MacroGenics (United States)), Francine Chen(MacroGenics (United States)), Monika Tomaszewska‐Kiecana(BioVirtus (Poland)), Monika Długosz‐Danecka(National Institute of Oncology), Halyna Pylypenko(Cherkasy State Technological University), Janine Koucheki(MacroGenics (United States)), Shakeela Bahadur(The University of Texas MD Anderson Cancer Center), Andrew Weickhardt(Austin Hospital), Susanna V. Ulahannan(Oklahoma State University Oklahoma City), John Muth(MacroGenics (United States)), Nada Hamad(UNSW Sydney), Patrick Kaminker(MacroGenics (United States)), Hua Li(Jiading District Central Hospital), Xiaoyu Zhang(Agilent Technologies (United States)), Jichao Sun(MacroGenics (United States)), Adam S. Asch(Cornell University), Paul A. Moore(Zymeworks (Canada))
Cited by 25
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532